Genedx Holdings Corp Stock Investor Sentiment

WGS Stock   80.46  1.75  2.22%   
Slightly above 56% of all GeneDx Holdings' private investors are looking to take a long position. The analysis of overall sentiment of trading GeneDx Holdings Corp stock suggests that some investors are interested at this time. GeneDx Holdings' investing sentiment can be driven by a variety of factors including economic data, GeneDx Holdings' earnings reports, geopolitical events, and overall market trends.
  

GeneDx Holdings Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards GeneDx Holdings can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
a day ago at investing.com         
Disposition of 5162 shares by Kevin Feeley of GeneDx Holdings at 75.3443 subject to Rule 16b-3
Investing News at Macroaxis
3 days ago at simplywall.st         
GeneDx Holdings Corp.s PS Is Still On The Mark Following 40 percent Share Price Bounce
Simply Wall St News at Macroaxis
few days ago at investing.com         
Genedx director Ryan sells shares worth 3.3 million
Investing News at Macroaxis
few days ago at finance.yahoo.com         
GeneDx to Participate in Upcoming Investor Conference
Yahoo News
few days ago at businesswire.com         
Disposition of 2108 shares by Kevin Feeley of GeneDx Holdings at 77.403 subject to Rule 16b-3
businesswire News
few days ago at thelincolnianonline.com         
Disposition of 38 shares by Kevin Feeley of GeneDx Holdings at 74.9651 subject to Rule 16b-3
news
few days ago at investing.com         
Disposition of 4272 shares by Jason Ryan of GeneDx Holdings at 70.502 subject to Rule 16b-3
Investing News at Macroaxis
few days ago at investing.com         
GeneDx CEO Katherine Stueland sells 3.2m in stock
Investing News at Macroaxis
few days ago at investing.com         
Mount Sinai Health System sells 10.4 million in GeneDx shares
Investing News at Macroaxis
few days ago at gurufocus.com         
Insider Sell Alert Katherine Stueland Sells 45,415 Shares of GeneDx Holdings Corp
Gurufocus Stories at Macroaxis
six days ago at finance.yahoo.com         
Next Gen Diagnostics Announces New York State Department of Healths Wadsworth Center Has Joined the ...
Yahoo News
six days ago at finance.yahoo.com         
Disposition of 774 shares by Jason Ryan of GeneDx Holdings at 72.2565 subject to Rule 16b-3
Yahoo News
six days ago at finance.yahoo.com         
GeneDx Fuels Rare Disease Drug Discovery with Launch of GeneDx Discover
Yahoo News
six days ago at gurufocus.com         
GeneDx Holdings Corp Trading 3.9 percent Higher on Nov 19
Gurufocus Stories at Macroaxis
over a week ago at finance.yahoo.com         
Disposition of 3131 shares by Katherine Stueland of GeneDx Holdings at 71.8318 subject to Rule 16b-3
Yahoo News
Far too much social signal, news, headlines, and media speculation about GeneDx Holdings that are available to investors today. That information is available publicly through GeneDx media outlets and privately through word of mouth or via GeneDx internal channels. However, regardless of the origin, that massive amount of GeneDx data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of GeneDx Holdings news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of GeneDx Holdings relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to GeneDx Holdings' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive GeneDx Holdings alpha.

GeneDx Holdings Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 717 shares by Kevin Feeley of GeneDx Holdings subject to Rule 16b-3
08/30/2024
2
Disposition of 262 shares by Kevin Feeley of GeneDx Holdings at 31.7096 subject to Rule 16b-3
09/03/2024
3
Disposition of 6546 shares by Katherine Stueland of GeneDx Holdings subject to Rule 16b-3
09/09/2024
4
Disposition of 897 shares by Saad Kareem of GeneDx Holdings at 9.2095 subject to Rule 16b-3
09/12/2024
5
Disposition of 2635 shares by Kevin Feeley of GeneDx Holdings at 37.59 subject to Rule 16b-3
09/16/2024
6
GeneDx Holdings Corp Q2 2024 Earnings Call Highlights Strong Revenue Growth and Improved ...
10/09/2024
7
Disposition of 130 shares by Ruch Joshua of GeneDx Holdings subject to Rule 16b-3
10/15/2024
8
GeneDx Holdings Corp Q3 2024 Earnings Call Highlights Record Revenue Growth and First ...
10/30/2024
9
Acquisition by Katherine Stueland of 18750 shares of GeneDx Holdings subject to Rule 16b-3
11/01/2024
10
GeneDx to Highlight Key Research Findings at American Society of Human Genetics Annual Meeting
11/04/2024
11
Zacks.com featured highlights include Snap, GeneDx and Leonardo
11/05/2024
12
GeneDx Holdings Corp Stock Price Up 5.28 percent on Nov 8
11/08/2024
13
40,573 Shares in GeneDx Holdings Corp. Acquired by Chartwell Investment Partners LLC
11/13/2024
14
Disposition of tradable shares by Katherine Stueland of GeneDx Holdings at 74.3389 subject to Rule 16b-3
11/15/2024
15
GeneDx Fuels Rare Disease Drug Discovery with Launch of GeneDx Discover
11/19/2024
16
Mount Sinai Health System sells 10.4 million in GeneDx shares
11/20/2024
17
Disposition of 60000 shares by Opko Health, Inc. of GeneDx Holdings at 33.8543 subject to Rule 16b-3
11/22/2024

Additional Tools for GeneDx Stock Analysis

When running GeneDx Holdings' price analysis, check to measure GeneDx Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GeneDx Holdings is operating at the current time. Most of GeneDx Holdings' value examination focuses on studying past and present price action to predict the probability of GeneDx Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GeneDx Holdings' price. Additionally, you may evaluate how the addition of GeneDx Holdings to your portfolios can decrease your overall portfolio volatility.